

# Coronavirus rapid antigen test for early diagnosis









Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)



## RIDA®QUICK SARS-CoV-2 Antigen

Art. No. N6803

Immunochromatographic rapid test for detection of SARS-CoV-2 nucleocapsid protein in human respiratory samples.

	Content:	
 for in vitro diagnostic use	1 x Test strip	50 pc.
 Consult instructions for use!	1 x Reagent A	2.8 ml
 23450	1 x Reagent B	2.8 ml
 2021-03	2 x Disposable pipet	50 pcs.
 2 to 8 °C	2 x Reagent vial	25 pcs.
 N6803		
 50		
 2020-12		

CE Do not reuse

R-Biopharm AG, An der neuen Bergstraße 17  
64297 Darmstadt, Germany  
Phone: +49 (0) 61 51 - 81 02-0  
www.r-biopharm.com

r-biopharm®



**Sensitive:**

95 % sensitivity compared to PCR with a Ct value of < 29



**Specific:**


100 % specificity compared to PCR



**Quality:**

Developed and manufactured in Germany under ISO 13485

More information:



[https://r-b.io/n6803\\_en](https://r-b.io/n6803_en)

# Rapid test information

## RIDA®QUICK SARS-CoV-2 Antigen

Art. No. N6803

### Your advantages



#### Accurate:

Immunochromatographic detection of the SARS-CoV-2 nucleocapsid antigen, no cross-reactivity with common human coronaviruses



#### Reliable:

High analytical sensitivity of 237 TCID50/mL



#### Dependable:

An integrated control line shows the validity of the result



#### Fast and simple:

Test system including swab system, qualitative visual evaluation without equipment, results in only 20 minutes

RIDA®QUICK SARS-CoV-2 Antigen, Art. No. N6803

### SARS-CoV-2

### Antigen diagnostic test

Rapid antigen tests are a good option for early diagnosis in people with a high viral load, which occurs 1 to 3 days prior to the start of symptoms and in the early symptomatic phase (within 5 to 7 days).<sup>1</sup>

Regulatory measures can be introduced quickly through the use of SARS-CoV-2 antigen tests.<sup>2</sup> Because it is relatively common, the nucleocapsid protein is the recommended target for rapid antigen tests. The WHO recommends a sensitivity of  $\geq 80\%$  and a specificity of  $\geq 97\%$  compared to PCR.<sup>1</sup>

#### Clinical sensitivity compared to PCR

PCR Ct value	<Ct28	<Ct29	<Ct30
Sensitivity	100 %	95 %	90 %

#### Clinical specificity compared to PCR

Specificity	100 %
-------------	-------



<sup>1</sup> Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance 11. September 2020. WHO Referenznummer: WHO/2019-nCoV/Antigen\_Detection/2020.1  
<sup>2</sup> European Centre for Disease Prevention and Control. COVID-19 testing strategies and objectives. 15. September 2020. ECDC: Stockholm; 2020.